TY - JOUR AU - Santoni, Matteo AU - Conti, Alessandro AU - Montironi, Rodolfo AU - Battelli, Nicola PY - 2018 TI - Editorial on “Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial” JF - Translational Cancer Research; Vol 7, Supplement 1 (February 06, 2018): Translational Cancer Research Y2 - 2018 KW - N2 - We read with great interest the paper entitled “ Adjuvant Treatment for High-Risk Clear Cell Renal Cancer Updated Results of a High-Risk Subset of the ASSURE Randomized Trial ” by Haas et al . (1). Last year, the same group published the results of a randomized phase III trial ASSURE comparing 1-year treatment with sorafenib (400 mg twice daily), sunitinib (50 mg/day for 4 weeks of every 6 weeks), or placebo as adjuvant therapies for patients with completely resected renal cell carcinoma (RCC), without reporting significant improvements of the disease-free survival (DFS) in the study arms (2). More recently, Ravaud and his group firstly showed the results of a 750-patient randomized study, S-TRAC (3), (sunitinib 50 mg daily with 4/2 schedule vs . placebo in clear cell RCC predominant pT3-4 or node-positive disease). UR - https://tcr.amegroups.org/article/view/18571